RenovoRx Expands IP Portfolio for Novel Drug-Delivery Platform RenovoRx, Inc. (Nasdaq: RNXT), a life sciences company focused on developing targeted oncology therapies and commercializing the FDA-cleared RenovoCath® delivery system, today emphasized its robust intellectual property (IP) portfolio. The company is…
Series E and E1 Warrant Exercises Secure $16.3 Million for Delcath Systems Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company dedicated to treating primary and metastatic liver cancers, announced today the exercise of 1.7 million Series E and Series…
Marinus Pharmaceuticals to Be Acquired by Immedica Immedica Pharma AB, a global leader in rare diseases, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company dedicated to enhancing the lives of patients with seizure disorders, have announced a merger agreement. Under…
CEL-SCI Prices $5 Million Public Offering CEL-SCI Corporation (NYSE American: CVM), a clinical-stage immunotherapy company focused on cancer treatments, today announced the pricing of a public offering of 16,130,000 shares of its common stock or pre-funded warrants (in lieu of…
Superior HealthPlan Marks 25th Anniversary with $25,000 Grant to NAMI El Paso Superior HealthPlan, a prominent managed care organization in Texas and a subsidiary of Centene Corporation (NYSE: CNC), announced a $25,000 grant to National Alliance on Mental Illness (NAMI)…
HCA Healthcare Appoints Wendy Warren as SVP & Chief Ethics Officer HCA Healthcare, Inc. (NYSE: HCA), one of the nation’s leading healthcare providers, has announced the appointment of Wendy Warren as senior vice president and chief ethics and compliance officer,…
Opdivo Qvantig™ FDA Approved for Subcutaneous Use in Adult Solid Tumor Indications Bristol Myers Squibb (NYSE: BMY) recently announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. This combination…
Gastric Cancer: TEVIMBRA Approved in U.S. for First-Line Treatment BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company set to change its name to BeOne Medicines Ltd., today announced that the U.S. Food and Drug Administration (FDA)…
Takeda Announces HYQVIA® 10% Injection Approval in Japan for Agammaglobulinemia Takeda (TSE:4502/NYSE:TAK) has announced that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the treatment of patients…
Kerecis Expands Silicone Fish-Skin Line with SurgiClose® Kerecis, a leader in the use of sustainably sourced fish skin and fatty acids for cellular therapy, tissue regeneration, and protection, has announced the launch of SurgiClose® Silicone. This innovative product combines fish-skin…
Wearables to Be Used by 50% of Older Adults for Life-Saving Alerts by 2034, Predicts ScienceSoft ScienceSoft has released a comprehensive report examining the future of wearables in preventive healthcare for older adults. The study, supported by data from statistical…
Tivic Health CEO’s Letter to Shareholders Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company pioneering bioelectronic medicine, has released its annual letter from the CEO to shareholders, highlighting key milestones in 2024 and setting the stage for exciting…